Navigation Links
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Date:1/7/2008

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) with safety and

tolerability comparable to placebo -

- Conference Call Scheduled for 4:00PM ET Today -

PRINCETON, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well-tolerated. Eighty-five (85%) of patients receiving R7128 1500mg and Pegasys plus Copegus achieved undetectable HCV RNA levels following 4 weeks of treatment with safety and tolerability comparable to placebo. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.

Dr. Michelle Berrey, Pharmasset's Chief Medical Officer, stated "R7128, in combination with Pegasys plus Copegus, has shown that nucleoside polymerase inhibitors can demonstrate Rapid Virologic Response (RVR) percentages that are similar to protease inhibitors with an acceptable short-term clinical safety profile. This study also suggests that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care that is not found with other classes of HCV inhibitors. The addition of R7128 at both dose levels to the current standard of care has demonstrated a greater percentage of RVR compared to the standa
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Latanoprost Market Investigation Report 2015-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... Diversifies Revenue Streams and Boosts Scale in Existing Generics ... Expected to be Immediately Accretive to Adjusted Diluted Earnings per ... Company Reiterates Full-Year 2010 Financial Guidance ... today that it has entered into a definitive agreement to ...
... (Nasdaq: DCTH ) announced today that management will ... Tuesday, October 5, 2010 at 8:45 a.m. ET in New ... an overview of the Company,s business strategy and recent corporate ... only. Delcath will offer a live audio webcast of its ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 2Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 3Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 4Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 5Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 6Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 7Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 8Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 9Delcath to Present at the William Blair Emerging Growth Stock Conference 2
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk for ... posted an article on the new research. Click here to read it now. ... French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the workers ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available on ... was required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations ... of the item’s selling price.” , With competitive pricing in the e-commerce market for ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN ... announced that it will be devoting an entire short segment to the subject of ... around the globe on a daily basis, but recent advancements in medical science may ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Health Foundation,s Annual Salute to Service Award , ... second consecutive year, Jim Kerwin of Oxford Communications ( ... announce that Oxford Communications will be the primary sponsor ... Award Luncheon on June 17th and Celebrity Golf Tournament ...
... Agency hopes to better explain its decisions to regain lost ... Food and Drug Administration, an agency long criticized for not ... it has created a task force to study how to ... to try and figure out how to make FDA and ...
... LAUDERDALE, Fla., June 2 LifeSync Corporation, the ... announced that Florida Hospital in Orlando has completed ... its Cardiovascular Institute for patients undergoing cardiovascular surgery. ... in the Florida Hospital System, houses the Florida ...
... This ... health care advocacy but it does little to help the public, says Erika Schwartz, MD ... (PRWEB) June 2, 2009 -- This week,s ... care advocacy but it does little to help the public, says Erika Schwartz, MD in her ...
... PEMBROKE, Bermuda, June 2 Darwin ... Company,Holdings, Ltd (NYSE: AWH ), today ... Manager, will be participating in a,panel at the American ... 3, 2009. The roundtable is titled "Market, Claims,and Healthcare ...
... , MILLERSVILLE, Md., June 2 Travel Advantage Network ... spring morning to support the National Alliance for Research ... kilometers of it. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090602/DC26325 ) ... support the charity by completing a 2.5K sponsored walk at ...
Cached Medicine News:Health News:Jim Kerwin Announces Oxford Communications To Be the Title Sponsor of Bermuda Health Foundation Salute for the Second Year 2Health News:FDA to Study Ways to Be More Open With Public 2Health News:FDA to Study Ways to Be More Open With Public 3Health News:Florida Hospital Cardiovascular Institute Completes House-Wide Implementation of the LifeSync(R) Wireless ECG System 2Health News:Florida Hospital Cardiovascular Institute Completes House-Wide Implementation of the LifeSync(R) Wireless ECG System 3Health News:Dr Erika Says Newsweek's Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 2Health News:Darwin's Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable, June 3, 2009 2Health News:Darwin's Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable, June 3, 2009 3Health News:A Little Bit of Leg Work Goes a Long Way for Travel Advantage Network and Mental Health Charity 2
... for Western Blot analysis ... Western Blot Analyzer for many applications including ... presence of infectious diseases such as viruses ... accurate screening of allergies and other application ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Store 200 to 350 Liters of ... Storage and Distribution of Purified Water,Millipores compact ... to store 200 to 350 liters of ... systems, and to maintain consistent purity of ...
... Liters of pure water, Complete, Compact Systems ... Water,Millipores compact S.D.S. Storage and Distribution Systems ... liters of purified water produced by Elix ... purity of stored water, provide effective protection ...
Medicine Products: